Trump is unlikely to end Medicare drug price talks — here’s what that means for patients and pharma

CNBC February 10, 2025
Annika Kim Constantino

Key Points

– President Donald Trump likely won’t do away with a process that allows Medicare to negotiate drug prices with manufacturers, even as he erases Joe Biden’s other policy accomplishments.

– But Trump will likely make some changes to those price talks, and it may not require help from Congress.

– Trump could either weaken the negotiations in a way that bodes well for the pharmaceutical industry, or try to achieve even deeper savings for patients and the federal government to outdo his predecessor.

President Donald Trump likely won’t do away with a landmark process that allows Medicare to negotiate drug prices with manufacturers, even as he moves to erase Joe Biden’s other historic policy accomplishments....

Today's Sponsors

Today's Sponsor